1 This study investigated whether a single administration of a range of doses (1, 4 and 8 mg kg 
Introduction
Decrease in the functional activity of central serotonergic and catecholaminergic systems is probably associated in major depressive episodes (Blier & De Montigny, 1994) . Applying an appropriate strategy with drugs targeting both neurotransmitter systems may improve the efficacy of the antidepressant treatment. In recent years, new antidepressant drugs, with less adverse effects than imipramine derivatives, have been developed that selectively block either the serotonin (5-hydroxytryptamine, 5-HT) transporter, that is, selective serotonin reuptake inhibitors (SSRIs), or the noradrenaline (NA) transporter (e.g. reboxetine), or block both, that is, mixed serotonin/noradrenaline reuptake inhibitors (SNRIs -venlafaxine, duloxetine) (Artigas, 1995; Vetulani & Nalepa, 2000) . SSRIs, such as paroxetine and citalopram, are effective in treating depressed patients (Delgado et al., 1992; Deakin & Dursun, 2002) , but it has been suggested that SNRIs such as venlafaxine, a compound that increased both extracellular levels of 5-HT ext) and NA ([NA] ext) in the rat frontal cortex (FCx) (Dawson et al., 1999; Millan et al., 2001) , should be a greater therapeutic success than SSRI in depressed patients (Einarson et al., 1999) .
The data obtained in vitro, in rat brain synaptosomal preparations (Bolden-Watson & Richelson, 1993; Barker et al., 1994) led to the classification of paroxetine as the most potent SSRI based on its very high affinity for the 5-HT transporter (K D 5-HT ¼ 0.29 nM). Citalopram is the most selective SSRI, being about 100-fold weaker in blocking the NA transporter than paroxetine in vitro (K D 5-HT /K D NA for citalopram ¼ 1.8 nM/6100 nM ¼ 1/3388; K D 5-HT /K D NA for paroxetine ¼ 0.29 nM/81 nM ¼ 1/279 (Sa´nchez & Hytell, 1999) ). However, the 5-HT/NA selectivity ratios measured in vitro, vary considerably between SSRIs (Sa´nchez & Hytell, 1999) . Animal studies are necessary to determine their pharmacological properties in vivo (potency (calculated ED 50 values) and efficacy (maximal response in a preclinical test)). Recent preclinical studies indicate that the selectivity of SSRIs for 5-HT over NA transporters might be less apparent in vivo. Indeed, in the mouse forced swimming test (FST) in Swiss mice, an animal model of depression which predicts the efficacy of antidepressant drugs in humans, paroxetine, citalopram and venlafaxine dose-dependently increased the mobility time (Bourin et al., 1998; Redrobe et al., 1998a, c) . Moreover, in this test, we demonstrated that paroxetine, as well as venlafaxine, display noradrenergic-like behavioural activity at a clinically relevant dose as low as 8 mg kg À1 in mice (Redrobe et al., 1998b, c) .
The main advantage of intracerebral in vivo microdialysis is to allow the simultaneous measurement of ext and [NA] ext at nerve terminal regions of the brain. This technique has already been performed to measure [NA] ext in rats, following administration of a single dose of SSRI systemically, but the results are inconsistent (Thomas et al., 1998; Bymaster et al., 2002; Koch et al., 2002) . Thus, the absence of intracerebral microdialysis data in mice led us to investigate the selectivity of both SSRIs, paroxetine and citalopram in vivo by using this technique in mice, to measure simultaneously cortical [5-HT]ext and [NA]ext. We used an experimental protocol similar to that used by Redrobe et al. (1998b) 
Methods

Animals
Male Swiss mice, 4 -6 weeks old, weighing 20 -24 g, were housed in our animal care facility in groups of 3 -6 and kept under standard conditions (room temperature of 22 -231C, 12 : 12 light -dark cycle, free access to food and water). Mice were tested between 10.00 a.m. and 4.00 p.m. during the light phase. Only mice with probes confined to the FCx were used for subsequent analysis of microdialysis data. Procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national and international laws and policies (Council directive #87 -848, October 19, 1987 , Ministe`re de l'Agriculture et de la Foreˆt, Service Ve´te´rinaire de la Sante´et de la Protection Animale, permissions #005037 to A.M.G.).
Treatment
Extracellular 5-HT and NA levels were measured in the FCx of awake, freely moving mice treated with 1, 4 or 8 mg kg
À1
, not corrected for the salt : base ratio of paroxetine, citalopram or venlafaxine intraperitoneally (i.p.). Control mice received saline (NaCl 0.9%) treatment given by the same route of administration.
For each drug administration, the effects on [5-HT]ext and [NA]ext were simultaneously measured in the same animal by using microdialysis probe implanted in the right and the left FCx, respectively.
Drugs and reagents
Paroxetine HCl (Glaxo SmithKline, U.K.), citalopram HBr (Lundbeck, Denmark) and venlafaxine HCl (Wyeth, U.S.A.) were dissolved in saline in a volume of 25 ml kg
À1
. The reagents used for analysis of dialysate levels of NA were sodium acetate trihydrate and citric acid monohydrate (Merck, Germany), 1-octanesulphonic acid sodium salt hydrate (Acros Organics, U.S.A.), disodium ethylenediaminetetraacetic acid (EDTA) (Sigma, U.S.A.), dibutylamine (Fluka chemie AG, Germany), methyl alcohol (SDS, France), noradrenaline bitartrate (Sigma, U.S.A.), perchloric acid and ascorbic acid (Merck, Germany).
Intracortical in vivo microdialysis studies in awake, freely moving mice Concentric dialysis probes were made of cuprophan fibres and set up as described previously (Malagie´et al., 2001) . All probes presented an active length of 2 mm for the FCx ( Â 0.30 mm outer diameter). Animals were anaesthetized with chloral hydrate (400 mg kg À1 , i.p.). They were placed in a stereotaxic frame and were implanted with two probes according to a mouse brain atlas (Franklin & Paxinos, 1997) : coordinates from bregma (in mm) of the left and right FCx:
. Animals were allowed to recover from the surgery overnight. The following day, approximately 20 h after the surgery, the probes were continuously perfused with an artificial cerebrospinal fluid (aCSF) (composition in mM: NaCl 147, KCl 3.5, CaCl 2 1.26, MgCl 2 1.2, NaH 2 PO 4 1.0, NaHCO 3 25.0, pH 7.470.2) at a flow rate of 1.5 ml/min using a CMA/ 100 pump (Carnegie Medicin, Stockholm, Sweden). At 1 h after the start of aCSF perfusion, four fractions were collected every 15 min to measure the basal values (mean7s.e.m. corresponding to B0 at t0) calculated for each mouse before systemic administration of either saline, paroxetine, citalopram or venlafaxine. For extracellular NA level measurements, 2 ml of an antioxidant mixture (100 mM perchloric acid 70 -72%, 50 mM L( þ ) ascorbic acid and 270 mM EDTA) was added in Eppendorf tubes to protect NA from degradation. After collections, samples were immediately frozen at À801C, then analysed with two different high-performance liquid chromatography (HPLC) methods, one for 5-HT as previously described (Malagie´et al., 2000; Gardier et al., 2003) , and another one for NA adapted from Malagie´et al. 
Analysis of 5-HT dialysats
Briefly, cortical dialysates were analysed for 5-HT by using a HPLC system (XL-ODS, 4.6 Â 75 mm, particle size 3 mM; Beckman) coupled to an amperometric detector (HP1049A, Hewlett-Packard, Les Ullis, France). The column was maintained at room temperature (E221C) and the flow rate of the mobile phase was 0.7 ml min À1 .
Analysis of NA in dialysates
The HPLC system consisted of a programmable solvent module 116, an isocratic pump (Beckman), in combination with a pulse damper, an automatic injector system (Carnegie Medicin, Stockholm, Sweeden) and a silica-based reverse-phase ) as main factor, followed by Fisher protected least significance difference (PLSD) post hoc test.
Data presentation and statistical analysis
In addition, the effects of antidepressant drugs on dialysate 5-HT and NA levels were calculated to yield a theoretical maximum effect (efficacy), as described by Tallarida & Murray (1987) . The ED 50 values (doses of antidepressant drugs that elicit a half-maximal increase in basal neurotransmitter levels) and 95% confidence intervals were calculated by using the computer software Prism 2.0 (GraphPad Software, Inc., U.S.A.). For this purpose, we used the two fractions in which we found a maximal effect in each mouse following antidepressant drug administration. The in vivo potency of these antidepressant drugs was calculated according to the method of Tallarida & Murray (1987) . The statistical differences of Emax 5-HT or Emax NA between antidepressants were determined by a Sidak post hoc test following a oneway ANOVA. The comparison between Emax 5-HT and Emax NA for a particular antidepressant drug (i.e., paroxetine and citalopram) was determined by the Mann -Whitney U-test. Statistical significance was set at Po0.05. (Figures 3c, d ). This increase was greater than those measured for the two SSRIs studied. 
Results
Effects
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The SSRIs as well as the SNRI induced statistically significant increases in [NA] (Figures 1b -d) (Figures 3c, d) .
In 
Efficacy of antidepressant drugs in vivo
The Emax values (% maximal increase7s.e.m.) are given in 
Discussion
In the present in vivo study, we found that a single administration of SSRIs (paroxetine, citalopram) and an SNRI (venlafaxine) induced increases in the extracellular levels of 5-HT and NA in the dialysates from the FCx of awake, freely moving mice. Depending on the antidepressant drugs studied, these increases occurred either at 1, 4 or 8 mg kg À1 given systemically. In our experimental conditions, citalopram and paroxetine have the highest potency to increase cortical 
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Antidepressants and noradrenaline outflow in mice was as follows: venlafaxine4citalopram4paroxetine. Furthermore, paroxetine was as efficient as citalopram in increasing cortical [NA] ext, and the efficacy of the two SSRIs studied on dialysate NA was greater than that of the SNRI, venlafaxine (paroxetine ¼ citalopram4venlafaxine). The FCx plays a crucial role in processes involved in the control of mood, cognition and motor behaviour, functions that are compromised in depression (Millan et al., 2000) . A perturbation of corticolimbic serotonergic and noradrenergic transmissions is implicated in the aetiology of depression, and antidepressant drugs elevating the monoamine neurotransmission in the FCx likely plays a role in depression therapy (Tanda et al., 1994; Gobert et al., 1997) . Preclinical studies have clearly shown that the 5-HT and NA systems interact extensively in the brain, and it would be difficult to investigate how a given molecule affects one system, without considering its influence on others (Gobert et al., 1997; Blier, 2001; Koch et al., 2002) . By using in vivo microdialysis in the FCx of awake mice, we tested whether SSRIs, such as paroxetine and citalopram, may act at both noradrenergic and serotonergic systems in the brain. As it would be expected from their ability to block potently the 5-HT transporter, we demonstrated that paroxetine and citalopram enhanced the dialysate levels of 5-HT in the FCx. Similar results have been obtained in this brain region by others in rats (Arborelius et al., 1996; Millan et al., 2001; Bymaster et al., 2002) and by our group in mice (Malagie´et al., 2001; 2002) , following administration of a single dose of SSRIs.
We also found that cortical [5-HT]ext looks stable in the range of paroxetine doses studied. Surprisingly, the effects of paroxetine decline at the highest dose tested. The absence of a statistically significant effect of the 8 mg kg À1 dose of paroxetine on cortical [5-HT]ext might be due to the randomization of our treated groups of mice.
In a previous behavioural study, we used the FST in Swiss mice to evaluate the possible noradrenergic-like activity of paroxetine (Redrobe et al., 1998b) . We found that a pretreatment with p-chlorophenylalanine (PCPA, a serotonin synthesis inhibitor) attenuated the antidepressant-like effect of a low dose of paroxetine in the FST, whereas a higher dose of this SSRI remained active. These data suggest that paroxetine displays both serotonergic and noradrenergic activities in the preclinical psychopharmacological test employed. Here, our neurochemical results obtained by using the microdialysis technique in Swiss mice are in line with those obtained in the FST. Indeed, both SSRIs, especially paroxetine, simultaneously elevated [NA] ext and [5-HT]ext in the FCx. Thus, these results observed with two different in vivo assays, behavioural and neurochemical approaches, the FST and the microdialysis study, respectively, led to the same conclusion: paroxetine may have effects on noradrenergic system in vivo in Swiss brain mice.
In vitro data indicate that citalopram is the most selective SSRI for inhibiting the neuronal 5-HT transporter, whereas paroxetine is the most potent one (Sa´nchez & Hytell, 1999) . Our experiment allowed us to characterize in vivo both SSRIs, analysing their potency and their efficacy in blocking 5-HT and NA transporters. In the dose range tested (i.e., 1, 4 and 8 mg kg As previously observed in rats (Romero & Artigas, 1997) , here, in mice we found that paroxetine reached a ceiling effect on ext when administered at relatively low doses, whereas citalopram and venlafaxine increased cortical [5-HT]ext dosedependently. However, paroxetine displayed the highest potency to increase cortical [NA]ext. Thus, when measuring AUC values, we clearly demonstrate that, even if paroxetine and citalopram belong to the same class of antidepressant drugs, their pharmacological profiles were different in vivo, following a single acute administration. These in vivo data barely correlate with in vitro data. The clinical relevance of the in vivo findings obtained here in mice is currently unknown.
Our study is the first which demonstrates an influence of a single administration of SSRI simultaneously on extracellular levels of 5-HT and NA in the FCx using microdialysis in awake, freely moving mice. Indeed, the effects of a single dose of SSRI on [NA]ext levels using intracerebral in vivo microdialysis technique in the FCx have been mainly studied in rats. However, major discrepancies regarding these effects of acute treatment with various SSRIs have been reported in the literature in this species. Fluvoxamine (12 mg kg À1 , i.p.) (Shachar et al., 1997) (Koch et al., 2002) . In addition, Millan et al. (1999; recently showed that citalopram increased [NA]ext in rat FCx, although an increase in [NA]ext was also found in salinetreated rats.
In contrast, sertraline did not alter noradrenaline release in rat cortex and hippocampus, when administered acutely (Thomas et al., 1998) . Hajo´s-Korcsok et al. (2000) showed in awake, freely moving rats that a single paroxetine dose of 5 mg kg À1 did not elevate [NA] ext in the hippocampus, while [5-HT]ext was increased. Conversely, in the FCx, it has been demonstrated that paroxetine increased NA levels following administration of a very high dose to rats (30 mg kg À1 ) (Beyer et al., 2002) . Different brain regions in the same species could lead to differences in the effect of the same SSRI on [NA]ext. The FCx is a complex neuronal system with widespread afferents of serotonergic, dopaminergic as well as noradrenergic neurons in rat (Lindvall et al., 1978) , suggesting that this brain area could be preferable to demonstrate the noradrenergic effect of SSRIs. In addition, the effects of paroxetine and citalopram seem to differ between species, since we measured an increase in cortical [NA]ext in mice for both SSRIs, whereas recently Bymaster et al. (2002) found that, with the exception of fluoxetine, SSRIs (citalopram, paroxetine and sertraline) did not increase [NA] ext in the rat FCx. Consistent with these latter microdialysis results, but not with ours obtained in mice, an electrophysiological study found that paroxetine had no effect on the firing of noradrenaline neurones in rats (Szabo et al., 1999) .
In our study, we compared the effects of the two SSRIs with those of venlafaxine because this SNRI was marketed as a dual 5-HT and NA reuptake inhibitor (Artigas, 1995) . We found that venlafaxine was inactive at 1 and 4 mg kg À1 in mice since it did not increase cortical ext and [NA]ext levels. Only the 8 mg kg À1 dose had a significant effect on dialysate levels of these neurotransmitters, the peak accumulation of 5-HT (410%) in the FCx being considerably greater than that of NA (141%). These results are somewhat surprising because
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venlafaxine is assumed to block NA reuptake in vivo at the dose we used. (Dawson et al., 1999) . Thus, the effects of venlafaxine on cortical [5-HT]ext and [NA]ext levels seem to differ between species (rats versus mice). However, Gur et al. (1999) found that an acute administration of venlafaxine resulted in dosedependent increases in cortical and hippocampal . The potency and selectivity of venlafaxine for 5-HT/NA systems have also been questioned (Beı¨que et al., 1998 ). An in vivo study has shown that the affinity of venlafaxine for the 5-HT transporter is greater than its affinity for the NA transporter (Gur et al., 1999) . Our neurochemical data suggest that, in mice, low doses of venlafaxine (o10 mg kg Our neurochemical data are consistent with the behavioural study of Redrobe et al. (1998c) regarding the antidepressantlike effect of venlafaxine in Swiss mice in the FST: at low doses, this SNRI displayed an activity indicative of in vivo inhibition of 5-HT reuptake, while at 8 mg kg À1 and higher doses it mobilized both serotonergic and noradrenergic brain neurotransmissions in the Swiss mice (Redrobe et al., 1998c) . However, in the present study, the profile of venlafaxine's effects differs from that of paroxetine at 8 mg kg À1 dose, the magnitude of antidepressant-like effect of venlafaxine in the FST is slightly greater (20%) than the size effect of paroxetine (14%) (Redrobe et al., 1998b, c) . Our microdialysis data suggest that the increase in cortical [5-HT] could play a more important role than NA in this antidepressant-like effect of venlafaxine.
Our microdialysis study clearly demonstrates that SSRIs, that is, paroxetine and citalopram, can not only increase cortical (Hughes & Stanford, 1996; Stanford, 1996) . The blockade of catecholamine reuptake by SSRIs has also been suggested by several studies (Owens et al., 2000; Shinkai et al., 2002) . Indeed, Shinkai et al. (2002) demonstrated that paroxetine competitively inhibited the functional activity of the NA transporter by acting on a desipramine-binding site. Similarly, noradrenaline efflux was increased during local infusion of either citalopram or fluoxetine (5 or 50 mM for 3 h) in the FCx of anaesthetized rats (Hughes & Stanford, 1996; 1998) . This effect was abolished by a pretreatment with a selective noradrenergic neurotoxin, suggesting that SSRI can directly bind to NA transporters located on noradrenergic neurones (Hughes & Stanford, 1998) . Since SSRIs were administered systemically in the present study, they may have blocked NA transporters either in the FCx (where the dialysis probe was implanted), or elsewhere in the brain. Further experiments studying the effects of a local infusion of these antidepressant drugs through a microdialysis probe implanted either into the FCx (at noradrenergic nerve terminals) or the locus coeruleus (the main source of noradrenergic cell bodies innervating the FCx) may help to clarify this issue. The NA transporter blockade seems to occur mainly in the locus coeruleus (LC), since local administration of citalopram by reverse dialysis in the LC increased [NA] ext in the LC, thus leading to the subsequent inhibition of LC neurones via alpha(2)-adrenoceptors in rats (Mateo et al., 2000) . Then, the decreased firing rate of noradrenergic neurones leads to decreased release of NA in the cortex.
The indirect hypothesis suggests that an increase in [5-HT]ext, resulting from the systemic administration of a SSRI, could secondly increase NA release in various nerve terminal areas of the brain. It implies that the activation of 5-HT heteroreceptors located on noradrenergic nerve terminals may occur in the present study. Mateo et al. (2000) concluded from their results (described above) that SSRI-induced NA release is dependent on the presence of endogenous 5-HT in the LC, since a pretreatment with PCPA prevented the effects of a local administration of citalopram on [NA]ext in rats. We have not investigated this hypothesis in mice yet, but Stanford (1996) excluded the indirect hypothesis as an explanation for the results of similar in vivo experiments.
The effects of antidepressants on serotonergic and noradrenergic neurones are not independent, because there is a close anatomical and functional relationship between the two pathways in the brain (Nutt, 2002) . In nerve terminal regions of the brain, through an unclear mechanism, SSRIs can produce an overall facilitation of noradrenergic transmission (Hughes & Stanford, 1996) . Bymaster et al. (2002) have shown that the increase in [NA] ext measured in the prefrontal cortex following administration of fluoxetine in the awake, freely moving rat was not due to a nonselective blockade of NA uptake, but to an interaction with the 5-HT 2C receptor subtype, blocking the serotonergic inhibitory control on NA release in the locus coeruleus. It has been also demonstrated that a systemic administration of 5-HT 1A receptor agonists increases NA release in the rat FCx through activation of postsynaptic 5-HT 1A heteroreceptors (Hajo´s-Korcsok et al., 1999) .
In conclusion, our data confirm that SSRIs lack selectivity in vivo to block the 5-HT transporter because these antidepressant drugs can simultaneously increase cortical ; venlafaxine at 8 mg kg À1 ). Our results suggest that paroxetine and citalopram, currently classified as SSRIs, can act as mixed 5-HT/NA reuptake inhibitors in vivo. For example, paroxetine can block both 5-HT and NA transporters in vivo at doses X4 mg kg À1 in mice, at least in the FCx. This idea has recently been supported by a clinical study in which NA and 5-HT transporter functions were assayed by using human transporter-transfected cells in the presence of serum collected from patients with major depressive disorder treated with paroxetine (Gilmor et al., 2002) . The clinical significance of this action of paroxetine on the brain noradrenaline transporter is currently unknown, but it may contribute to its broad therapeutic efficacy since it can be prescribed either in the treatment of depression or in anxiety disorders. Our results are especially important because several clinical studies have revealed that using drugs that block both NA and 5-HT transporters in the brain may represent a more effective antidepressant treatment for severe or refractory depression than a single selective treatment (Nelson, 1998; Thase et al., 2001) .
